Technical Analysis for AGIO - Agios Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 42.15 -2.52% -1.09
AGIO closed down 2.52 percent on Monday, August 10, 2020, on 1.76 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical AGIO trend table...

Date Alert Name Type % Chg
New Downtrend Bearish 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Lower Bollinger Band Walk Weakness -2.52%
Wide Bands Range Expansion -2.52%
Oversold Stochastic Weakness -2.52%
Doji - Bullish? Reversal -2.88%
Lower Bollinger Band Walk Weakness -2.88%
Lower Bollinger Band Touch Weakness -2.88%
Oversold Stochastic Weakness -2.88%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and inborn errors of metabolism (IEMs) in the United States. Its products include AG-221, an oral inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations, as well as for the Type II D-2 hydroxyglutaric aciduria treatment; AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations; and enzyme glutaminase that converts the nutrient glutamine into the metabolite glutamate. The company's products also comprise AG-348, an oral small molecule activator of PKR enzyme for the treatment of patients with pyruvate kinase deficiency. It has a collaboration agreement with Celgene Corporation. The company was founded in 2007 and is based in Cambridge, Massachusetts.
Chemistry Biopharmaceutical Cancer Cancers Organic Chemistry Inborn Errors Of Metabolism Agios Pharmaceuticals Pyruvate Kinase Deficiency

Is AGIO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 56.745
52 Week Low 27.774
Average Volume 620,858
200-Day Moving Average 45.27
50-Day Moving Average 50.57
20-Day Moving Average 49.19
10-Day Moving Average 45.66
Average True Range 2.25
ADX 25.79
+DI 11.66
-DI 35.60
Chandelier Exit (Long, 3 ATRs ) 49.46
Chandelier Exit (Short, 3 ATRs ) 48.01
Upper Bollinger Band 57.59
Lower Bollinger Band 40.79
Percent B (%b) 0.08
BandWidth 34.14
MACD Line -2.38
MACD Signal Line -1.41
MACD Histogram -0.9715
Fundamentals Value
Market Cap 2.04 Billion
Num Shares 48.4 Million
EPS -6.33
Price-to-Earnings (P/E) Ratio -6.66
Price-to-Sales 59.19
Price-to-Book 6.21
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 45.18
Resistance 3 (R3) 45.22 44.24 44.68
Resistance 2 (R2) 44.24 43.47 44.23 44.51
Resistance 1 (R1) 43.20 42.99 42.71 43.16 44.34
Pivot Point 42.22 42.22 41.98 42.21 42.22
Support 1 (S1) 41.18 41.45 40.69 41.14 39.96
Support 2 (S2) 40.20 40.97 40.19 39.79
Support 3 (S3) 39.16 40.20 39.63
Support 4 (S4) 39.12